LY3561774

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

DyslipidemiasHyperlipoproteinemiaLipid Metabolism DisordersMetabolic Diseases

Phase 1

A Study of LY3561774 in Participants With Dyslipidemia

CompletedNCT04644809

Eli Lilly and CompanyDyslipidemias

Start: 2020-11-30End: 2022-05-17Updated: 2022-08-10

Phase 2

A Study of LY3561774 in Participants With Mixed Dyslipidemia

CompletedNCT05256654

Eli Lilly and CompanyDyslipidemias, Hyperlipoproteinemia, Lipid Metabolism Disorders +1

Start: 2022-07-20End: 2024-05-23Updated: 2025-03-17

Related Papers

Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial.

2025-03-3116 citations

Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies.

2025-03-304 citations

Abstract 12705: Identification and Characterization of Solbinsiran, a GalNAc Conjugated siRNA Targeting Angiopoietin-Like 3

Circulation2023-11-074 citations